The ongoing debates and nomenclature change and reclassification are apparently over, and adenomas and now referred to as Pit-Net’s (pituitary neuroendocrine tumors). Is this good, bad, or indifferent? These are complicated matters, so to shed some more light on the subject, we’ve invited some experts to discuss them. In today’s live talk, I’m joined by co-host and PWN cofounder Dr. Lewis Blevins; as you all know, Dr. Blevins is the Medical Director of the California Center for Pituitary disorders at UCSF. Also with us is Dr. Manish Aghi. Dr. Aghi is a frequent contributor to PWN and an attending Neurosurgeon California Center for Pituitary Disorders. Professor of Neurological Surgery and Principal Investigator, UCSF Brain Tumor Research Center’’ We are also delighted to welcome Dr. Arie Perry. Dr. Perry is the director of neuropathology at UCSF; he specializes in diagnosing benign and cancerous nervous system tumors, including those of the brain, spinal cord, and peripheral nerves. He is also a specialist in classifying the molecular genetics of tumors, which can be used to help determine the best treatment. To learn more, this PWN article provides additional background and reading on the subject.
Note: The background on the featured image is Hematoxylin and Eason views of pituitary adenomas. The light brownish granules represent staining for different hormones. The first was a patient with a prolactinoma, and the second was acromegaly to the first staining prolactin and the next growth hormone.
© 2022, Pituitary World News. All rights reserved.